在杜尔瓦卢马布加特雷梅利卢马布治疗不可切除的肝细胞癌时,肝功能发生变化
Nobuharu Tamaki1, Nami Mori2, Shintaro Takaki2
1Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Anticancer research
|August 28, 2024
概括
对于不可切除的肝细胞癌 (HCC) 的杜尔瓦卢马布加特雷梅利马布 (DT) 治疗没有显著影响肝功能,根据白素-白素 (ALBI) 评分进行测量. 这表明DT在HCC治疗期间保持肝功能.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 医学瘤学 医学瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 在肝细胞癌 (HCC) 治疗期间,维持肝功能至关重要.
- 结合杜尔瓦卢马布和特梅利卢马布 (DT) 对HCC患者肝功能的影响尚未得到充分证实.
研究的目的:
- 评估DT治疗不可切除的HCC期间肝功能变化.
- 评估DT在维持HCC患者肝功能方面的安全性和有效性.
主要方法:
- 一项全国性的多中心研究,涉及80名接受DT治疗的无法切除的HCC患者.
- 主要结局:在基线,第8周,第12周和进展性疾病 (PD) 时,白蛋白-白素 (ALBI) 评分的变化.
主要成果:
- 与基线相比,在第8周,第12周或PD时没有观察到ALBI得分的显著差异.
- 对2级ALBI患者或接受二线或后期治疗的患者的亚组分析也没有显示肝功能恶化.
结论:
- 杜尔瓦卢马布加上特梅利卢马布 (DT) 治疗有效地维持肝功能,在治疗不可切除的HCC的整个治疗过程中.
- 维护肝功能是DT的重要优势,特别是作为不可切除的HCC的第一线治疗.
相关概念视频
Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


